The Potential Use of HIV Vaccines for the Treatment of HIV Infection: Scientific Summary of the State-of-the-Art
Table 1. (Continued) Vaccine Expression System HIV Adjuvant or Vaccine Candidate Production Method Strain Delivery System Developer References Core protein/peptides: HGP-30 Ty.p24.VLP Synthetic p17 peptide Portion p17/p24 plus yeast transposon product baculovirus/insect rp24 Recombinant poxvirus: LAI LAI LAI LAI MN alum alum alum Mi croGeneSys Viral Technologies, Inc. British Bio-tech. Ltd. 6, 22 21 7, 51 23, 24 4, 5 vac-gp160 vac-gp160 CP-gp160 Recombinant vaccinia Recombinant vaccinia Recombinant canarypox Bristol-Myers Squibb/ Oncogen G. Beaud, InstitutJacques Monod Pasteur-MerieuxConnaught (Virogenetics) Immune Response Corp. J.-L. Excler, ersonal communication, 992 Whole Inactivated HIV-1: Whole inactivated HIV Beta-propi ol actone and y-irradiation inactivation HZ321 IFA 8 CD4 as immunoqen: Recombinant CD4 mammal i an IFA Biogen Anti-idiotype approach: N. Letvin, personal communication, 1992 J. Merritt, personal communication, 1992 19 Anti -gpl20 Anti -CD4 idiotype (lOT4) Immunogl obul in SAF IDEC Monoclonal antibody Alum Immunotech SA * Adapted from reference 54 ** LAI = group of HIV isolates which includes LAV, + DOC = Leoxycholate IFA = Incomplete Freund's adjuvant IIIB, BRU, etc.
-
Scan 1
Page #1
-
Scan 2
Page #2
-
Scan 3
Page #3
-
Scan 4
Page 1
-
Scan 5
Page 2
-
Scan 6
Page 3
-
Scan 7
Page 4
-
Scan 8
Page 5
-
Scan 9
Page 6
-
Scan 10
Page 7
-
Scan 11
Page 8
-
Scan 12
Page 9
-
Scan 13
Page 10
-
Scan 14
Page 11
-
Scan 15
Page 12
-
Scan 16
Page 13
-
Scan 17
Page 14
-
Scan 18
Page 15
-
Scan 19
Page 16
-
Scan 20
Page 17
-
Scan 21
Page 18
-
Scan 22
Page #22
-
Scan 23
Page #23
-
Scan 24
Page #24
-
Scan 25
Page #25
-
Scan 26
Page #26
-
Scan 27
Page #27
-
Scan 28
Page #28
-
Scan 29
Page #29
-
Scan 30
Page #30
-
Scan 31
Page #31
-
Scan 32
Page #32
-
Scan 33
Page #33
-
Scan 34
Page #34
-
Scan 35
Page #35
-
Scan 36
Page #36
-
Scan 37
Page #37
-
Scan 38
Page #38
-
Scan 39
Page #39
-
Scan 40
Page #40
-
Scan 41
Page #41
-
Scan 42
Page #42
-
Scan 43
Page #43
-
Scan 44
Page #44
-
Scan 45
Page #45
-
Scan 46
Page #46
-
Scan 47
Page #47
-
Scan 48
Page #48
About this Item
- Title
- The Potential Use of HIV Vaccines for the Treatment of HIV Infection: Scientific Summary of the State-of-the-Art
- Author
- National Institutes of Health (U.S.)
- Canvas
- Page #23
- Publication
- 1992-11-23
- Subject terms
- reports
- Series/Folder Title
- Government Response and Policy > Law > gp160 trials and controversy > National Institute of Health (U.S.) GP160 Meeting, Blue-Ribbon Panel (1992)
- Item type:
- reports
Technical Details
- Collection
- Jon Cohen AIDS Research Collection
- Link to this Item
-
https://name.umdl.umich.edu/5571095.0463.013
- Link to this scan
-
https://quod.lib.umich.edu/c/cohenaids/5571095.0463.013/23
Rights and Permissions
The University of Michigan Library provides access to these materials for educational and research purposes, with permission from their copyright holder(s). If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission.
Related Links
IIIF
- Manifest
-
https://quod.lib.umich.edu/cgi/t/text/api/manifest/cohenaids:5571095.0463.013
Cite this Item
- Full citation
-
"The Potential Use of HIV Vaccines for the Treatment of HIV Infection: Scientific Summary of the State-of-the-Art." In the digital collection Jon Cohen AIDS Research Collection. https://name.umdl.umich.edu/5571095.0463.013. University of Michigan Library Digital Collections. Accessed June 25, 2025.